Claris Injectables

Claris Injectables is an Indian pharmaceutical company.

History

2016: Baxter buys Claris Injectables for $625m

In December 2016, the American manufacturer of medical devices Baxter International announced the purchase of Claris Injectables for $625 million, taking into account the debts of the company being absorbed. It is planned to close the deal in the second half of 2017, first regulators must approve it.

At this time, Claris Injectables is developing injectable drugs that are sold worldwide. Claris drugs are used in intensive care, nephrology, etc. The company offers blood products, anesthesia products, analgesics and antibacterial drugs.

The acquisition of Claris Injectables will expand Baxter's presence in the rapidly growing global injectable drug market and accelerate our growth in the most important medicines that benefit patients around the world, says Baxter Chairman and CEO Jose Almeida. - The opportunities we receive with Claris Injectables will complement our differentiated technology, expertise and broad medical channel presence, paving the way for Baxter to become a world leader in reproducible injectable medicines.

According to forecasts of Claris Injectables, in 2016 the company's revenue will be $100 million, the margin on EBITDA - about 30-35%. USA bring in about half of Claris revenue, other developed markets - about 20%. Developing regions account for 30% of the pharmaceutical company's turnover.

In addition to Baxter, interest in buying Claris was shown by private equity firms Blackstone, Apax and Warburg Pincus, according to The Economic Times. The publication became aware of the upcoming sale of Claris in October 2016.^[1]

Notes